

# NBT Quality Policy



At NeoBiotechnologies, we are committed to advancing science and transforming cancer treatment through the discovery, development, and delivery of innovative **“ANTIBODIES”**. To achieve this, our Quality Policy is rooted in the principles of excellence, compliance, and continuous improvement.

## 1. Customer-Centric Approach

We strive to understand and meet the needs of our clients, providing reliable, high-quality monoclonal antibodies and other cutting-edge solutions for research and clinical applications. Customer satisfaction and trust are at the heart of everything we do.

## 2. Regulatory Compliance

We adhere strictly to all applicable regulatory requirements, including international standards governing quality and safety in biotechnology. Our processes are designed to meet and exceed these regulations to ensure product and service Quality.

## 3. Operational Excellence

We maintain Quality Management Systems (QMS) to ensure consistent production, traceability, and risk mitigation. Through teamwork and innovative practices, we aim to reduce errors and optimize resources, contributing to the overall success of our mission.

## 4. Continuous Improvement

Through regular training, audits, and performance evaluations, we promote a culture of continuous improvement, empowering our team to achieve higher standards of efficiency, quality, and sustainability.

## 5. Sustainability & Responsibility

We are committed to ethical practices and environmentally responsible operations, ensuring a positive impact on our community, employees, and the global biotechnology landscape

This policy underpins our unwavering dedication to quality and drives us to achieve breakthroughs that improve lives, aligning with our vision to lead in immuno-oncology research and innovation.

**Dr. Atul Tandon - MAB MAN**  
**President & CEO, NeoBiotechnologies**